Gottfried Rudofsky1, Andrei-Mircea Catarig2, Lucie Favre3, Katrine Grau2, Susan Häfliger4, Robert Thomann5, Bernd Schultes6. 1. Cantonal Hospital Olten, Clinic of Endocrinology and Metabolic Diseases, Olten, Switzerland. Electronic address: gottfried.rudofsky@spital.so.ch. 2. Novo Nordisk A/S, Søborg, Denmark. 3. Division of Endocrinology, Diabetology and Metabolism, Lausanne University Hospital, Lausanne, Switzerland. 4. Novo Nordisk Pharma AG, Zürich, Switzerland. 5. Stoffwechselzentrum BSS, Solothurn, Switzerland. 6. Metabolic Center St. Gallen, St. Gallen, Switzerland.
Abstract
AIMS: SURE Switzerland (NCT03631186) investigated real-world once-weekly (OW) semaglutide use in adults with type 2 diabetes (T2D). METHODS: This multicentre, prospective, observational study enrolled adults with T2D with ≥ 1 documented HbA1c value ≤ 12 weeks before semaglutide initiation. Primary endpoint was change in HbA1c from baseline to end of study (EOS; ~30 weeks). Secondary endpoints included changes in body weight (BW) and waist circumference (WC), and the proportion of patients achieving HbA1c < 8.0%, <7.5% and <7.0% at EOS. Semaglutide dose at EOS was a prespecified exploratory endpoint. RESULTS: Overall, 214 patients initiated semaglutide (baseline HbA1c 7.8% [62 mmol/mol], BW 99.9 kg and WC 117.4 cm); 187 attended the EOS visit. At EOS, 175 (81.8%) were still receiving semaglutide (mean [SD] dose 0.78 [0.29] mg); in those patients, mean HbA1c reduced by -0.8 [95% CI - 1.01;-0.68] %-points (-9 [-11;-7] mmol/mol), BW by -5.0 kg [-5.73;-4.24] and WC by -4.8 cm [-5.75;-3.79] (all p < 0.0001). At EOS, 85.9%, 76.5% and 55.9% patients achieved, respectively, HbA1c < 8.0%, <7.5% and < 7.0%. No new safety signals were identified. CONCLUSIONS: Patients with T2D in Switzerland initiating OW semaglutide experienced clinically relevant glycaemic control and BW improvements in a real-world setting, supporting semaglutide use in routine clinical practice.
AIMS: SURE Switzerland (NCT03631186) investigated real-world once-weekly (OW) semaglutide use in adults with type 2 diabetes (T2D). METHODS: This multicentre, prospective, observational study enrolled adults with T2D with ≥ 1 documented HbA1c value ≤ 12 weeks before semaglutide initiation. Primary endpoint was change in HbA1c from baseline to end of study (EOS; ~30 weeks). Secondary endpoints included changes in body weight (BW) and waist circumference (WC), and the proportion of patients achieving HbA1c < 8.0%, <7.5% and <7.0% at EOS. Semaglutide dose at EOS was a prespecified exploratory endpoint. RESULTS: Overall, 214 patients initiated semaglutide (baseline HbA1c 7.8% [62 mmol/mol], BW 99.9 kg and WC 117.4 cm); 187 attended the EOS visit. At EOS, 175 (81.8%) were still receiving semaglutide (mean [SD] dose 0.78 [0.29] mg); in those patients, mean HbA1c reduced by -0.8 [95% CI - 1.01;-0.68] %-points (-9 [-11;-7] mmol/mol), BW by -5.0 kg [-5.73;-4.24] and WC by -4.8 cm [-5.75;-3.79] (all p < 0.0001). At EOS, 85.9%, 76.5% and 55.9% patients achieved, respectively, HbA1c < 8.0%, <7.5% and < 7.0%. No new safety signals were identified. CONCLUSIONS:Patients with T2D in Switzerland initiating OW semaglutide experienced clinically relevant glycaemic control and BW improvements in a real-world setting, supporting semaglutide use in routine clinical practice.
Authors: P Marzullo; T Daffara; C Mele; M Zavattaro; A Ferrero; M Caputo; F Prodam; G Aimaretti Journal: J Endocrinol Invest Date: 2022-04-16 Impact factor: 5.467
Authors: Maria Dolores Garcia de Lucas; Jose Pablo Miramontes-González; Beatriz Avilés-Bueno; Ana Isabel Jiménez-Millán; Francisco Rivas-Ruiz; Luis M Pérez-Belmonte Journal: Front Endocrinol (Lausanne) Date: 2022-09-16 Impact factor: 6.055
Authors: Monika Kellerer; Margit Staum Kaltoft; Jack Lawson; Lasse Lykke Nielsen; Krzysztof Strojek; Ömür Tabak; Stephan Jacob Journal: Diabetes Obes Metab Date: 2022-06-29 Impact factor: 6.408